The Lancet Oncology
Fecha de publicación: 23 March 2020
Autores: Prof Michael Koller, PhD, Omar Shamieh, MD, Prof Marianne J Hjermstad, PhD, Kjersti Hornslien, MD, Teresa Young, BSc, Tara Chalk, et al.
Background: The European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Lung Cancer 13 (QLQ-LC13) assesses quality of life (QOL) in patients with lung cancer and was the first EORTC module developed for use in international clinical trials. Since its publication in 1994, major treatment advances with possible effects on QOL have occurred. These changes called for an update of the module and its international psychometric validation. We aimed to investigate the scale structure and psychometric properties of the updated lung cancer module, QLQ-LC29, in patients with lung cancer.Leer más